Benitec Biopharma Inc. (BNTC): Price and Financial Metrics

Benitec Biopharma Inc. (BNTC): $0.25

0.00 (-0.40%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

Add BNTC to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#354 of 504

in industry

BNTC Price/Volume Stats

Current price $0.25 52-week high $2.10
Prev. close $0.25 52-week low $0.13
Day low $0.23 Volume 78,100
Day high $0.25 Avg. volume 339,157
50-day MA $0.22 Dividend yield N/A
200-day MA $0.27 Market Cap 6.96M

BNTC Stock Price Chart Interactive Chart >

BNTC Stock Summary

  • BNTC has a higher market value than only 2.14% of US stocks; more precisely, its current market capitalization is $5,820,081.
  • BNTC's price/sales ratio is 85.59; that's higher than the P/S ratio of 97.34% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNTC comes in at -307.28% -- higher than that of only 1.75% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to BENITEC BIOPHARMA INC, a group of peers worth examining would be IKT, SABS, GNFT, BLDP, and BYSI.
  • BNTC's SEC filings can be seen here. And to visit BENITEC BIOPHARMA INC's official web site, go to www.benitec.com.

BNTC Valuation Summary

  • BNTC's price/earnings ratio is -0.3; this is 101.24% lower than that of the median Healthcare stock.
  • BNTC's price/sales ratio has moved up 70.1 over the prior 94 months.

Below are key valuation metrics over time for BNTC.

Stock Date P/S P/B P/E EV/EBIT
BNTC 2023-05-23 86.8 1.3 -0.3 0
BNTC 2023-05-22 82.4 1.2 -0.3 0
BNTC 2023-05-19 85.3 1.2 -0.3 0
BNTC 2023-05-18 80.9 1.2 -0.3 0
BNTC 2023-05-17 77.9 1.1 -0.3 0
BNTC 2023-05-16 89.7 1.3 -0.3 0

BNTC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BNTC has a Quality Grade of F, ranking ahead of 1.09% of graded US stocks.
  • BNTC's asset turnover comes in at 0.004 -- ranking 417th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows BNTC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 1 -36.612
2020-06-30 0.007 1 -8.634
2019-06-30 0.718 1 2.070
2018-06-30 0.214 1 -3.387
2017-06-30 0.521 1 -2.375
2016-06-30 0.020 1 -18.246

BNTC Price Target

For more insight on analysts targets of BNTC, see our BNTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.00 Average Broker Recommendation 2 (Hold)

Benitec Biopharma Inc. (BNTC) Company Bio


Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.


BNTC Latest News Stream


Event/Time News Detail
Loading, please wait...

BNTC Latest Social Stream


Loading social stream, please wait...

View Full BNTC Social Stream

Latest BNTC News From Around the Web

Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

9 subjects enrolled into the OPMD clinical development programHAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Third Fiscal Quarter ended March 31, 2023. The Company has filed its quarterly report on Form 10-Q for the

Yahoo | May 15, 2023

Benitec Biopharma to Present at the OPMD International Conference

9 OPMD subjects are now enrolled on the Natural History (NH) StudyHAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present virtually on the BB-301

Yahoo | May 8, 2023

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm ET.

Yahoo | May 8, 2023

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

First subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Second Fiscal Quarter ended December 31, 2022. The Company has filed its quarterly report on Form 10-Q

Yahoo | February 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!

William White on InvestorPlace | February 7, 2023

Read More 'BNTC' Stories Here

BNTC Price Returns

1-mo 17.92%
3-mo -21.88%
6-mo 31.58%
1-year -72.83%
3-year -96.65%
5-year -99.34%
YTD 47.06%
2022 -93.51%
2021 -12.67%
2020 -60.78%
2019 -66.00%
2018 -49.32%

Continue Researching BNTC

Want to see what other sources are saying about Benitec Biopharma LTD's financials and stock price? Try the links below:

Benitec Biopharma LTD (BNTC) Stock Price | Nasdaq
Benitec Biopharma LTD (BNTC) Stock Quote, History and News - Yahoo Finance
Benitec Biopharma LTD (BNTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!